ArticleExperimental and therapeutic medicine2026
Impact of older age on prognosis in hypersensitivity pneumonitis: A systematic review and meta-analysis.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity pneumonitis (HP) is a heterogeneous immune-mediated interstitial lung disease with markedly variable clinical outcomes. Increasing age has been repeatedly suggested as a determinant of worse prognosis; however, to the best of our knowledge, its independent prognostic impact has not been systematically quantified. A systematic review and meta-analysis were conducted in the present study in accordance with PRISMA guidelines and registered in PROSPERO (CRD420251004649). Medline, Google Scholar and Cochrane databases were searched from 1980 to 2025 for studies evaluating the association between older age and adverse outcomes in HP. Eligible studies included adult HP populations with comparative age data and reported prognostic outcomes, including mortality, rapid forced vital capacity decline, respiratory failure and need for long-term oxygen therapy. A random-effects model was applied, and heterogeneity was assessed using the I² statistic. A total of six observational studies comprising 1,518 patients with HP were included. Across studies, older age consistently associated with poorer outcomes, including increased mortality, higher likelihood of fibrotic disease and greater risk of respiratory failure. In studies reporting age as a continuous variable, pooled analysis demonstrated that each additional year of age was associated with a 5.4% increase in the hazard of death (pooled hazard ratio=1.054; 95% CI 1.030-1.079), with moderate heterogeneity (I²=36.4%); sensitivity analyses confirmed the robustness of the findings. Advanced age is a significant adverse prognostic factor in HP, independently associated with increased mortality and disease progression. These findings support the incorporation of age into prognostic models and risk stratification strategies and highlight the need for age-adapted diagnostic vigilance and individualized management approaches in older patients with HP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.